Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice

The protocol describes a method for injecting tumor cells through the percutaneous puncture route into cisterna magna that robustly induces leptomeningeal metastasis in mice, reducing trauma and extracranial tumor burden.

Leptomeningeal metastasis (LM), the spread of cancer cells into the cerebrospinal fluid (CSF)-filled leptomeninges, is a rare yet devastating complication of advanced solid tumors. Patients with LM often have a poor prognosis, with survival measured in weeks to months. Developing in vivo models that accurately replicate the complexities of LM is essential for understanding its cellular and pathological mechanisms and evaluating potential therapies. Murine LM models are typically created through intra-cardiac, carotid artery, or cisterna magna injection of tumor cells. However, intra-cardiac or carotid injections often result in substantial extracranial and brain tumor burden, complicating bioluminescent imaging and leading to mortality unrelated to LM. Meanwhile, conventional cisterna magna injection requires invasive procedures, such as skin incision and muscle dissection, making it both traumatic and resource intensive. Here, we describe a minimally invasive procedure for tumor cell injection into the leptomeningeal space through the cisterna magna without the need for a skin incision. This approach reduces extracranial tumor formation, minimizes surgical trauma, and shortens the time and postoperative care required compared to other surgical methods. Importantly, it consistently induces LM with minimal brain parenchyma infiltration, as confirmed by two-photon microscopy and histological analysis. This streamlined approach offers an efficient and reliable model for studying LM in preclinical research.

The metastatic disease remains the greatest challenge for patients with advanced cancers. Leptomeningeal metastasis (LM) refers to the spread of cancer cells to the pia mater, arachnoid mater, and subarachnoid space. LM from solid tumors is becoming increasingly common in lung cancer (9%-25%), breast cancer (5%-20%), and melanoma (6%-18%)^1,2, largely due to longer survival and improved diagnostic techniques. Cancer cells can invade the leptomeningeal space by multiple routes, including 1) direct invasion through peripheral structures such as dura mater, bone, and nerves; 2) hematogenous spread through the venous system; and 3) entry through the arterial circulation, where cancer cells slip through fenestrated vessels into the choroid plexus and subsequently into the cerebrospinal fluid-filled ventricles^3,4,5. Tumor cells entering the leptomeningeal space encounter multiple challenges, including deprivation of growth factors, limited metabolic intermediates, and hypoxic conditions⁶. However, due to the lack of appropriate tools and techniques, how tumor cells navigate these pathways and overcome inhospitable conditions to colonize the leptomeningeal space is poorly understood. Despite advances in multimodal therapies, including radiotherapy, systemic treatment, and intrathecal injection therapy, the prognosis for LM patients remains poor, with survival typically ranging from 2 to 4 months^3,7,8,9. Thus, there is an urgent need for a deeper understanding of the biology of leptomeningeal metastasis to improve current treatments and develop novel, targeted therapies. Achieving this requires the development of in vivo models that recapitulate the complex features of LM.

Unlike metastases in organs like the liver, bone, and brain, LM usually develops years after the diagnosis of the primary tumor^10,11,12. Similarly, in mouse models with spontaneous metastasis, LM is rare due to its low incidence and the fact that mice typically succumb to metastases at other sites. Experimental murine LM models can be created through various methods, including intracardiac, intracarotid artery, or, alternatively, direct injection into the cisterna magna or cerebral ventricles. While intracardiac injection of cancer cells is widely used⁹, it often results in a significant extracranial tumor burden, causing mortality unrelated to LM. Alternative approaches, such as injecting tumor cells through the carotid artery^13,14, require extensive specialized resources and result in large surgical incisions, which are traumatic. Moreover, this method also primarily leads to metastasis within the brain tissues itself, rather than leptomeninges, and is time-consuming and inefficient for establishing LM models¹⁵. Injection into the cisterna magna enables direct delivery of tumor cells to the leptomeningeal space. Several studies have used this approach to investigate LM mechanisms and evaluate new treatments^6,16,17.

In this manuscript, we present a convenient trans-cisterna magna injection protocol involving a direct percutaneous puncture to rapidly and stably generate a larger quantity of mice with LM. This method bypasses the brain-blood barrier and, therefore, enables efficient xenograft of tumor cells in the leptomeninges space. It also significantly reduces the surgical trauma and procedure time while reliably inducing LM in mice. We confirmed the occurrence of LM with minimal infiltration into the brain parenchyma, as verified by two-photon microscopy and histological analysis. Therefore, the resulting model faithfully replicates the complex microenvironment of LM, providing a valuable tool to study disease-associated cellular and pathological mechanisms and evaluate potential therapies.

All animal procedures in this manuscript were reviewed and approved by the ZJU-Laboratory Animal Welfare and Ethics Review Committee (ZJU20230155). C57BL/6J and NSG mice were obtained from and housed under specific-pathogen-free conditions at the ZJU Laboratory Animal Center. This protocol uses the murine lung cancer cell line, Lewis lung carcinoma (LLC1), and human lung cancer cell line, A549, both labeled with GFP and firefly luciferase. Both cell lines are kindly provided by Dr. Xiang H. F. Zhang (Baylor College of Medicine, USA)¹⁸. Here, we use LLC1 cells as an example. The procedure for the injection of A549 cells is almost identical, except that 6 x 10⁴ A549 cells were injected into NSG mice.

1. Preparation of cancer cells for injection

1. Culture 1.0 x 10⁶ LLC1 cells in DMEM supplemented with 10% fetal bovine serum (FBS) and 0.1 mg/mL penicillin-streptomycin at 37 °C in a 5% CO₂ incubator. When cells reach 70%-90% confluency, trypsinize them for 1 min using 2 mL of 0.25% Trypsin/EDTA solution. Centrifuge the cells at 300 x g for 3 min, wash them 2x with ice-cold PBS, and re-suspend them in 1 mL of phosphate-buffered saline (PBS).
2. Assess the concentration of viable cells using a Trypan Blue solution and a hemocytometer¹⁹. Ensure the cell viability is greater than 90%, with the majority of cells being single. Adjust the cell concentration to 2 x 10⁶ cells/mL in ice-cold PBS.
3. Aliquot 50 µL of the cell suspension into separate microcentrifuge tubes to avoid repeatedly pipetting.
4. Keep the cell suspensions on ice until ready for injection. Inject 10 µL of GFP-Luciferase-labeled LLC1 cells per mouse in this protocol, corresponding to 2 x 10⁴ cells per mouse.
   NOTE: Adjust the cell number as needed based on the metastatic kinetics of the injected cell lines.

2. Mice preparation

NOTE: In this study, male C57BL/6J mice, aged 6-8 weeks, were used.

1. Autoclave all surgical instruments and gloves packed with surgical drapes. Sanitize the benchtop and non-surgical equipment with 75% ethanol, then cover the work area with waterproof drapes.
2. Prepare a clean animal housing cage and a warming pad for post-procedure recovery.
3. Anesthetize the mouse by subcutaneously injecting 2% tribromoethanol (200 mg/kg). Check the depth of anesthesia using a pinch test before proceeding. Apply sterile ophthalmic ointment to protect the eyes from corneal damage once the mouse is anesthetized.
4. Shave the fur from the posterior occipital region using clippers, followed by applying depilatory creams to completely remove the fur in the same region.
5. Position the mouse prone with its neck placed over a 15 mL centrifuge tube. Secure the head and lower back with tape and palpate the space between the occiput and C1 vertebra with the index finger (Figure 1).
6. Disinfect the posterior occipital region by three rounds of wiping with 75% ethanol-soaked sterile cotton swabs, followed by betadine surgical scrub. Cover the non-sterile parts of the animal with a sterile drape.

3. Cisterna magna injection

NOTE: Aseptic techniques are required for the following steps, including the use of personal protective equipment and sterile gloves.

1. Gently pipet the cell suspension and aspirate 10 µL for injection with a 31G, 8 mm insulin syringe.
2. Palpate the area between the occiput and C1 of the mouse with index finger to locate the precise puncture site at the lower median margin of the posterior occipital skull. Mark this site if necessary.
3. Insert the needle at a 45°-50° angle into the cisterna magna through the identified puncture site, advancing to a depth of 4 mm. A distinct breakthrough sensation indicates that the needle has successfully entered the cisterna magna.
   1. If the puncture site is difficult to locate, make a small 3-5 mm incision at ear level to expose the posterior midline. If a surgical incision is required, administer Meloxicam (5 mg/kg/day) and Buprenorphine (0.1 mg/kg) subcutaneously 1 h prior to surgery.
4. Slowly inject the cell suspension by advancing the syringe plunger, keeping the syringe steady with the hand placed on the table.
5. After inoculation, hold the syringe in place for an additional 10 s to allow intracranial pressure to equilibrate. Then, withdraw the needle and press the puncture site with a sterile cotton swab for 1-2 min.

4. Post-injection care

1. Transfer the animals to clean cages on a heating pad and monitor them closely until they have fully recovered.
   1. In case an incision is made, close the wound using tissue glue and clips. Administer additional pain medication for 2-3 days post-surgery to control pain and aid recovery.
2. Monitor the mice closely for 7 days following the procedure and check the physical activities of animals and the appearance surrounding the injection site daily.

5. Assessment of leptomeningeal tumor growth

1. Bioluminescence imaging
   1. Anesthetize the mouse and administer D-luciferin (150 µg/g) in the retroorbital vein. Place the mice into the imaging chamber, positioning them in a designated nose cone on the anesthesia manifold. Use light baffles between animals to minimize signal interference.
   2. Image the animals immediately using the IVIS system with the exposure time between 0.5 s to 2 min⁶. Confirm successful tumor cell inoculation in the leptomeningeal space by a dispersive bioluminescent signal across the head and spinal cord (Figure 2A).
   3. Monitor the progression of LM by bioluminescence imaging every 4 days. Adjust imaging intervals based on tumor growth kinetics.
2. Histological analysis
   1. Anesthetize the mice when they were significantly less active or had lost 20% of their body weight and cut the skin and ribs to expose their thoracic cavity. Carefully insert a blunt-tipped cannula into the left ventricle and advance the cannula into the ascending aorta. Perfuse the animal with 20 mL of PBS through the cannula slowly.
   2. Use scissors to remove the head and make a midline scalp incision to expose the skull. Excise the surrounding soft tissues. Cut along the orbital ridge, then insert scissors into the foramen magnum, and carefully advance along the inner surface of the skull with upward pressure to avoid tissue damage.
   3. Remove the cranial bones, and then gently extract the brain. Fix the brain in 4% paraformaldehyde at 4 °C for 24 h and then equilibrate it into 15% sucrose PBS solution for 24 h, followed by 30% sucrose PBS solution for another 24 h at 4 °C.
   4. Place the tissue in a cryomold filled with Optimal Cutting Temperature (OCT) compound and then store it on dry ice for 30 min²⁰.
   5. Cut the OCT-embedded brain into 10 µm thick sections using a cryostat. Store the sections in a -80 °C freezer until further application.
   6. Perform Hematoxylin/Eosin (H&E) staining on the brain slides²¹. The presence of tumor cells at the brain edge indicates that metastasis occurs exclusively in the leptomeningeal space (Figure 3 and Table 1).
3. Two-photon microscopy
   1. Anesthetize the mice with LM. Remove the scalps covering the dorsal skull surface with forceps and scissors. Use a scalpel blade to remove the thin periosteum from the surface of the skull.
   2. Thin the skull with an abrasive drill until the pial vessels are visible through the thinned skull. Stabilize the observation area of the mouse head with a triangular headpiece secured by tissue adhesive^22,23.
   3. Administer 0.025 mL of 5% (w/v) TRITC-dextran in an infraorbital vein to label the blood vessels²².
   4. Perform two-photon microscopy through the imaging windows and reconstruct the leptomeningeal space (Figure 4). Detect the bone by second harmonic fluorescence at 450 nm emission with 900 nm excitation²⁴. Visualize GFP-labelled tumor cells and dextran-labelled vessels by collecting fluorescence signals at 507 nm and 572 nm emission with 900 nm and 1000 nm excitation, respectively.
4. Stereo fluorescence microscope
   1. Remove the mouse brain and place it under a stereomicroscope. Visualize GFP-labeled cells using a GFP-specific filter set (Figure 5).

Figure 1 illustrates the placement of the mouse for injection and the puncture site from lateral and front views. Figure 2 shows representative in vivo bioluminescence images of animals tested for generating LM through different approaches. GFP-luciferase-labeled LLC1 cells were injected into the animals through different routes, followed by bioluminescent imaging. As shown in Figure 2A, 10 days after ...

LM is an aggressive and fatal condition. Once the tumor cells metastasize to the cerebrospinal fluid-filled space, they rapidly disseminate throughout the entire central nervous system²⁵. These cells settle and invade the brain, spinal cord, cranial, and spinal nerves, ultimately leading to rapid neurological deterioration and eventual death¹⁷. To better understand the underlying pathophysiological mechanisms and evaluate potential therapeutic strategies, it is crucial to d...

The authors declare no conflict of interest.

The authors thank the Zhang laboratory members for their valuable discussions and assistance throughout this study. W.Z. is supported by the Fundamental Research Funds for the Zhejiang Provincial Universities (2023QZJH60), the Science Fund Program for Distinguished Young Scholars from the National Natural Science Foundation of China (588020-X42306/041), and the startup fund from the Life Sciences Institute of Zhejiang University.